Navigation Links
The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
Date:4/8/2009

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer

SAN DIEGO, April 8 /PRNewswire/ -- Celladon Corporation today announced the publication of results from a Phase 1/2 trial of MYDICAR(R) (AAV1/SERCA2a), a genetically targeted enzyme replacement therapy for advanced heart failure, in the April 2009 issue of the Journal of Cardiac Failure. The CUPID clinical trial demonstrated acceptable safety and produced quantitative evidence of biological activity across a number of parameters important for assessing heart failure. MYDICAR is designed to restore levels of an enzyme, SERCA2a, known to play a key role in the progression of heart failure. Repairing this molecular defect in animal studies has been shown to reverse the disease and restore cardiac function.

"Despite important therapeutic advances in pharmacologic and device therapies, the prognosis of patients with chronic heart failure remains extremely poor. Moreover, heart transplantation and the use of implantable assist devices are considered only in the later stages of the disease, and access to such therapies is restricted to a fraction of patients in need," said Brian E. Jaski, M.D., Medical Director of Advanced Heart Failure, Sharp Memorial Hospital, San Diego Cardiac Center, San Diego, a principal investigator on the study, and a lead author of the publication. "The CUPID trial is the first to attempt to rescue a failing heart by replacing an enzyme known to play a critical role in normal cardiac muscle cell activity. Our objective is not only to improve the symptoms of heart failure, but restore physiologic function and reverse the severity of the disease in this chronic patient population."

The results of this study include data from the Phase 1 portion of this ongoing Phase 1/2 study for Cohorts 1 a
'/>"/>

SOURCE Celladon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
2. NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations
3. American Association for Cancer Research (AACR) Deploys Collexis Reviewer Finder and Journal Dashboard Applications
4. Evidence of Ancient Hot Springs on Mars Detailed in Astrobiology Journal
5. Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine
6. Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award
7. Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience
8. BioSpace Partners with Journal of Visualized Experiments (JoVE) to Offer Peer-Reviewed Scientific Video Content on BioSpace.com
9. Tips from the journals of the American Society for Microbiology
10. Elsevier Introduces The American Journal of Medicine Blog
11. Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
(Date:9/18/2014)... 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... compounds and metabolic processes, is pleased to announce the addition ... Ms. Nola E. Masterson , a California ... effective September 17, 2014. "We,re very pleased ... board," states Andrew Dahl , President and CEO. "She ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global and Chinese Stem Cell Industry Report, ... Stem cells are undifferentiated biological cells that can differentiate ... produce more stem cells. Stem cell therapy can be ... of hematological system disease), nervous system diseases, damage or ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Leatherwood ... FM-4910 listed material, to stay competitive in the ... These high-performance materials ultimately impact product quality and ... and owner. , Established in 1980 in Lewisville, ... as many fabricators have left the business. Much ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... 15, 2006, the Supreme Court in eBay Inc. v. ... proves infringement should be granted an injunction must be ... (1) irreparable injury; (2) inadequacy of remedies at law; ... The Court rejected the Federal Circuit's approach that an ...
... encounter, we reviewed the list of the leading Big Pharma companies of ... some of the leading pharmaceuticals products and deals of 2005. , ... Product/Company Disease Area ... Lipitor (Pfizer) Cholesterol Reduction $12.9 +6% ...
... Inc., a developer of protein chip technologies, has ... the National Institutes of Health to develop a test ... ,An estimated 50 million Americans suffer from mild to ... especially for children and senior citizens. GenTel's protein chips ...
Cached Biology Technology:Supreme Court decision in eBay case could affect value of patents 2Big Pharma's continued hunger and search for new products 2Big Pharma's continued hunger and search for new products 3Big Pharma's continued hunger and search for new products 4GenTel gets federal grant to develop allergy test 2GenTel gets federal grant to develop allergy test 3
(Date:9/19/2014)... the sake of fairness per se but in order ... Frans de Waal, PhD, and Sarah Brosnan, PhD, co-authors ... is defined as a negative reaction to unequal outcomes. ... , Their conclusion comes after the co-authors reviewed more ... it is the evolution of forestalling partner dissatisfaction with ...
(Date:9/19/2014)... study shows that legume plants regulate their symbiotic ... that are transmitted through the plant structure from ... of bacteria-holding nodules in the roots. This collaborative ... Institute for Basic Biology, the Graduate University for ... Sustainable Resource Science in Japan. , Legumes, ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3For legume plants, a new route from shoot to root 2No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... number of rivers and lakes are being invaded by exotic ... Such species represent a threat to native species, as they ... the case of the mudsnail Potamopyrgus antipodarum ... and has spread throughout rivers, lakes or streams in Europe, ...
... found that silicone foul release coatings may be an important ... water and hydropower infrastructure. Allen D. Skaja, Ph.D., PCS, of ... metal alloys over three years at Parker Dam on the ... to reduce the rate of mussel settlement, and any attached ...
... Calif. ( www.ucr.edu ) Research by Nosang ... Riverside, Bourns College of Engineering, has enabled a ... that can detect small quantities of harmful airborne ... Economy Corporation company, has completed the prototype which ...
Cached Biology News:Survival without water: A key trait of an aquatic invader to spread 2'Electronic nose' prototype developed 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: